Industry veteran Todd Zavodnick, Excellergy President and CEO, talks to TDD about his newest endeavor and the promise of allergic effector cell response inhibitors (ECRIs) in IgE-mediated diseases including chronic spontaneous urticaria.
Industry veteran Todd Zavodnick, Excellergy President and CEO, talks to TDD about his newest endeavor and the promise of allergic effector cell response inhibitors (ECRIs) in IgE-mediated diseases including chronic spontaneous urticaria.